Screener
Bioventus BVS Restorative Therapies — Total Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Bioventus’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:43 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001665988-26-000042
| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
|---|---|---|---|---|
| Net sales | $153,208 | $147,660 | $285,297 | $271,536 |
| Cost of sales (including depreciation and amortization of $9,893, $10,603, $19,980 and $20,868, respectively) | 47,542 | 45,570 | 88,862 | 86,390 |
| Gross profit | 105,666 | 102,090 | 196,435 | 185,146 |
| Selling, general and administrative expense | 82,740 | 79,110 | 161,065 | 152,612 |
| Research and development expense | 3,173 | 3,172 | 5,640 | 6,183 |
| Restructuring costs | (415) | — | 39 | — |
| Depreciation and amortization | 1,041 | 1,439 | 2,148 | 3,032 |
| Loss on disposals | — | 1 | — | 82 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bioventus's restorative therapies — total net sales?
- Bioventus (BVS) reported restorative therapies — total net sales of $21.11M in Q2 2026.
- How has Bioventus's restorative therapies — total net sales changed year-over-year?
- Bioventus's restorative therapies — total net sales decreased by 2.4% year-over-year, from $21.64M to $21.11M.
- What is the long-term trend for Bioventus's restorative therapies — total net sales?
- Over 4 years (2021 to 2025), Bioventus's restorative therapies — total net sales has grown at a -8.5% compound annual growth rate (CAGR), from $121.57M to $85.37M.
- What does restorative therapies — total net sales mean?
- This metric represents the total revenue generated from the sale of products and services within the restorative therapies business unit, net of returns, allowances, and discounts. It serves as a primary indicator of market demand and the commercial success of the company's regenerative medicine and orthopedic healing portfolio. Tracking this figure helps investors assess the growth trajectory and competitive positioning of the segment within the broader medical technology market.
Ask your AI about Bioventus's restorative therapies — total net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude